Legal Representation
Attorney
Joshua S. Jarvis, Esq.
Application History
6 events| Date | Code | Type | Description |
|---|---|---|---|
| Feb 21, 2025 | GNS3 | O | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
| Feb 21, 2025 | CNSL | R | SUSPENSION LETTER WRITTEN |
| Feb 21, 2025 | GNSL | F | LETTER OF SUSPENSION E-MAILED |
| Feb 19, 2025 | DOCK | D | ASSIGNED TO EXAMINER |
| Aug 12, 2024 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Aug 12, 2024 | NWAP | I | NEW APPLICATION ENTERED |
Detailed Classifications
Class 005
Pharmaceutical preparations for the treatment of immune system related diseases and disorders, complement-mediated diseases and disorders, neurological diseases and disorders, and ophthalmic diseases and disorders; pharmaceutical preparations for the treatment of Guillain-Barré syndrome, macular degeneration, geographic atrophy, Huntington's Disease, amyotrophic lateral sclerosis (ALS), lupus, cold agglutinin disease (CAD), chronic inflammatory demyelinating polyneuropathy (CIDP), and myasthenia gravis (MG).
Class 042
Pharmaceutical research and development; consulting services in the field of pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials.
Class 044
Providing medical information; providing medical information related to pharmaceuticals.
Classification
International Classes
005
042
044
USPTO Documents
Click to view cached USPTO documents for this trademark
Only administrators can request new documents from USPTO